Nanoscale perfluorocarbon expediates bone fracture healing through selectively activating osteoblastic differentiation and functions.
Bone fracture
Differentiation
Healing
Nano-PFC
Osteoblast
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
03 Jun 2020
03 Jun 2020
Historique:
received:
18
03
2020
accepted:
25
05
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
2
2
2021
Statut:
epublish
Résumé
Fracture incidence increases with ageing and other contingencies. However, the strategy of accelerating fracture repair in clinical therapeutics remain a huge challenge due to its complexity and a long-lasting period. The emergence of nano-based drug delivery systems provides a highly efficient, targeted and controllable drug release at the diseased site. Thus far, fairly limited studies have been carried out using nanomedicines for the bone repair applications. Perfluorocarbon (PFC), FDA-approved clinical drug, is received increasing attention in nanomedicine due to its favorable chemical and biologic inertness, great biocompatibility, high oxygen affinity and serum-resistant capability. In the premise, the purpose of the current study is to prepare nano-sized PFC materials and to evaluate their advisable effects on promoting bone fracture repair. Our data unveiled that nano-PFC significantly enhanced the fracture repair in the rabbit model with radial fractures, as evidenced by increased soft callus formation, collagen synthesis and accumulation of beneficial cytokines (e.g., vascular endothelial growth factor (VEGF), matrix metalloprotein 9 (MMP-9) and osteocalcin). Mechanistic studies unraveled that nano-PFC functioned to target osteoblasts by stimulating their differentiation and activities in bone formation, leading to accelerated bone remodeling in the fractured zones. Otherwise, osteoclasts were not affected upon nano-PFC treatment, ruling out the potential target of nano-PFC on osteoclasts and their progenitors. These results suggest that nano-PFC provides a potential perspective for selectively targeting osteoblast cell and facilitating callus generation. This study opens up a new avenue for nano-PFC as a promising agent in therapeutics to shorten healing time in treating bone fracture.
Sections du résumé
BACKGROUND AND RATIONALE
OBJECTIVE
Fracture incidence increases with ageing and other contingencies. However, the strategy of accelerating fracture repair in clinical therapeutics remain a huge challenge due to its complexity and a long-lasting period. The emergence of nano-based drug delivery systems provides a highly efficient, targeted and controllable drug release at the diseased site. Thus far, fairly limited studies have been carried out using nanomedicines for the bone repair applications. Perfluorocarbon (PFC), FDA-approved clinical drug, is received increasing attention in nanomedicine due to its favorable chemical and biologic inertness, great biocompatibility, high oxygen affinity and serum-resistant capability. In the premise, the purpose of the current study is to prepare nano-sized PFC materials and to evaluate their advisable effects on promoting bone fracture repair.
RESULTS
RESULTS
Our data unveiled that nano-PFC significantly enhanced the fracture repair in the rabbit model with radial fractures, as evidenced by increased soft callus formation, collagen synthesis and accumulation of beneficial cytokines (e.g., vascular endothelial growth factor (VEGF), matrix metalloprotein 9 (MMP-9) and osteocalcin). Mechanistic studies unraveled that nano-PFC functioned to target osteoblasts by stimulating their differentiation and activities in bone formation, leading to accelerated bone remodeling in the fractured zones. Otherwise, osteoclasts were not affected upon nano-PFC treatment, ruling out the potential target of nano-PFC on osteoclasts and their progenitors.
CONCLUSIONS
CONCLUSIONS
These results suggest that nano-PFC provides a potential perspective for selectively targeting osteoblast cell and facilitating callus generation. This study opens up a new avenue for nano-PFC as a promising agent in therapeutics to shorten healing time in treating bone fracture.
Identifiants
pubmed: 32493334
doi: 10.1186/s12951-020-00641-2
pii: 10.1186/s12951-020-00641-2
pmc: PMC7271395
doi:
Substances chimiques
Fluorocarbons
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Subventions
Organisme : Natural Science Foundation of Beijing Municipality
ID : Z171100000417025
Organisme : Natural Science Foundation of Beijing Municipality
ID : 8191002
Organisme : National Natural Science Foundation of China
ID : 21637004
Organisme : National Natural Science Foundation of China
ID : 21920102007
Références
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4578-83
pubmed: 15755807
Nano Lett. 2016 Oct 12;16(10):6145-6153
pubmed: 27622835
Molecules. 2019 Jul 19;24(14):
pubmed: 31331121
Trends Cell Biol. 2004 Feb;14(2):86-93
pubmed: 15102440
Front Endocrinol (Lausanne). 2012 Jul 20;3:88
pubmed: 22833734
Front Chem. 2017 Oct 31;5:89
pubmed: 29164105
Int J Med Sci. 2018 May 14;15(7):723-729
pubmed: 29910677
Bone. 2013 Jan;52(1):220-9
pubmed: 23063782
Blood. 2010 Jan 7;115(1):140-9
pubmed: 19887675
Res Vet Sci. 2018 Jun;118:11-18
pubmed: 29334646
Injury. 2008 Sep;39 Suppl 2:S45-57
pubmed: 18804573
Iowa Orthop J. 2012;32:90-4
pubmed: 23576927
Oncol Res Treat. 2018;41(4):166-171
pubmed: 29562226
Eur Cell Mater. 2012 Jul 09;24:1-17
pubmed: 22777949
Arch Dermatol. 2007 Oct;143(10):1252-6
pubmed: 17938338
Artif Cells Blood Substit Immobil Biotechnol. 2005;33(1):47-63
pubmed: 15768565
J Orthop Res. 2019 Jan;37(1):35-50
pubmed: 30370699
Cell Death Dis. 2017 Sep 7;8(9):e3037
pubmed: 28880271
Nat Commun. 2019 Apr 5;10(1):1580
pubmed: 30952842
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6152-7
pubmed: 25918395
Oxid Med Cell Longev. 2019 Aug 14;2019:5738368
pubmed: 31485296
Anesthesiology. 2002 Dec;97(6):1338-49
pubmed: 12459658
Nanomedicine. 2018 Oct;14(7):2271-2282
pubmed: 30076934
Cell Mol Biol Lett. 2016 Nov 16;21:26
pubmed: 28536628
Biomaterials. 2011 Oct;32(29):7068-78
pubmed: 21704367
Mol Cancer Res. 2009 Aug;7(8):1224-33
pubmed: 19671689
Artif Cells Blood Substit Immobil Biotechnol. 1994;22(4):1281-5
pubmed: 7849934
Chem Phys Lett. 2012 Jan 10;521(C):91-97
pubmed: 22347721
Artif Organs. 2010 Aug;34(8):622-34
pubmed: 20698841
Biomaterials. 2006 Jun;27(18):3351-60
pubmed: 16488005
Bone. 2020 Mar;132:115209
pubmed: 31866495
Theranostics. 2018 Sep 9;8(18):4898-4911
pubmed: 30429876
Nat Rev Endocrinol. 2019 Nov;15(11):651-665
pubmed: 31462768
Exp Ther Med. 2016 Dec;12(6):3541-3544
pubmed: 28101149
J Cell Biochem. 2011 Dec;112(12):3582-93
pubmed: 21793044
Cell Metab. 2013 Feb 5;17(2):249-60
pubmed: 23395171
Vet Comp Orthop Traumatol. 2019 Jul;32(4):297-304
pubmed: 31319431
Bone Res. 2013 Sep 25;1(3):203-15
pubmed: 26273504
Blood. 1996 Nov 15;88(10):4029-39
pubmed: 8916970
Endocrinology. 2000 May;141(5):1667-74
pubmed: 10803575
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):209-28
pubmed: 11311993
Eur J Pharm Biopharm. 2004 Mar;57(2):369-75
pubmed: 15018998
J Orthop Res. 2014 Sep;32(9):1117-9
pubmed: 24895294
J Microsc. 2017 Aug;267(2):130-142
pubmed: 28319261
Int J Mol Sci. 2019 Aug 16;20(16):
pubmed: 31426273
Front Cell Dev Biol. 2017 May 04;5:45
pubmed: 28523266
Small. 2017 Apr;13(15):
pubmed: 28195425
Adv Drug Deliv Rev. 2015 Nov 1;94:3-12
pubmed: 26428617
Exp Ther Med. 2018 Oct;16(4):3478-3484
pubmed: 30233698
ACS Nano. 2014 Jun 24;8(6):5898-910
pubmed: 24806912
J Control Release. 2018 Mar 10;273:51-67
pubmed: 29407678
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 Sep-Oct;1(5):492-501
pubmed: 19920872
Ultrasonics. 2014 Sep;54(7):2024-33
pubmed: 24965563
J Orthop Res. 2007 Jan;25(1):51-61
pubmed: 17019699
Nanoscale. 2017 Jul 27;9(29):10161-10166
pubmed: 28702585
Clin Orthop Relat Res. 2011 Nov;469(11):3118-26
pubmed: 21409457
FASEB J. 2019 Feb;33(2):2574-2586
pubmed: 30285579
Thyroid. 2011 Aug;21(8):897-906
pubmed: 21745106
Adv Drug Deliv Rev. 2015 Nov 1;94:41-52
pubmed: 25895621
Bone Rep. 2019 Apr 26;10:100206
pubmed: 31193232
Metabolism. 2011 Dec;60(12):1655-63
pubmed: 21632079
ACS Nano. 2017 Sep 26;11(9):9445-9458
pubmed: 28881139
Tissue Eng Part B Rev. 2017 Jun;23(3):268-280
pubmed: 27846781
Front Physiol. 2017 Nov 14;8:927
pubmed: 29184512
J Bone Miner Metab. 2009;27(1):114-9
pubmed: 19057837
Mater Sci Eng C Mater Biol Appl. 2017 Jun 1;75:688-698
pubmed: 28415516
HSS J. 2010 Feb;6(1):85-94
pubmed: 19763695
J Dent. 2015 Mar;43(3):382-8
pubmed: 25456611
Int J Mol Med. 2013 Jun;31(6):1411-7
pubmed: 23563320
Curr Drug Targets. 2015;16(14):1671-81
pubmed: 26601723